Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Primary melanoma of the bladder: Case report and review of the literature.

Barillaro F, Camilli M, Dessanti P, Gorji N, Chiesa F, Villa A, Pastorino A, Aschele C, Conti E.

Arch Ital Urol Androl. 2018 Sep 30;90(3):224-226. doi: 10.4081/aiua.2018.3.224. Review.

2.

Phase II Study of Preoperative Treatment with External Radiotherapy Plus Panitumumab in Low-Risk, Locally Advanced Rectal Cancer (RaP Study/STAR-03).

Pinto C, Di Bisceglie M, Di Fabio F, Bochicchio A, Latiano T, Cordio S, Rosati G, Aschele C, Marino A, Bergamo F, Bustreo S, Frassineti L, Ciardiello F, Damato A, Giaquinta S, Baldari D, Boni L.

Oncologist. 2018 Aug;23(8):912-918. doi: 10.1634/theoncologist.2017-0484. Epub 2018 Mar 9.

3.

Authors' reply to "Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: potential pitfalls of a multicentre observational study".

Pucciarelli S, Valentini V, Aschele C, Barina A.

Tech Coloproctol. 2018 Feb;22(2):143-144. doi: 10.1007/s10151-018-1747-8. Epub 2018 Jan 15. No abstract available.

PMID:
29335852
4.

Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM).

Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD.

ESMO Open. 2017 Apr 12;2(1):e000147. doi: 10.1136/esmoopen-2016-000147. eCollection 2017. Review.

5.

Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study.

Barina A, De Paoli A, Delrio P, Guerrieri M, Muratore A, Bianco F, Vespa D, Asteria C, Morpurgo E, Restivo A, Coco C, Pace U, Belluco C, Aschele C, Lonardi S, Valentini V, Mantello G, Maretto I, Del Bianco P, Perin A, Pucciarelli S.

Tech Coloproctol. 2017 Aug;21(8):633-640. doi: 10.1007/s10151-017-1665-1. Epub 2017 Jul 28.

PMID:
28755256
6.

Precoagulation-assisted parenchyma-sparing laparoscopic liver surgery: rationale and surgical technique.

Francone E, Muzio E, D'Ambra L, Aschele C, Stefanini T, Sani C, Falco E, Berti S.

Surg Endosc. 2017 Mar;31(3):1354-1360. doi: 10.1007/s00464-016-5120-6. Epub 2016 Jul 21.

PMID:
27444829
7.

Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D; European Society for Medical Oncology (ESMO); European Society of Surgical Oncology (ESSO); European Society of Radiotherapy and Oncology (ESTRO).

Eur J Surg Oncol. 2014 Oct;40(10):1165-76. doi: 10.1016/j.ejso.2014.07.030.

PMID:
25239441
8.

Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D.

Ann Oncol. 2014 Sep;25 Suppl 3:iii10-20. doi: 10.1093/annonc/mdu159. Epub 2014 Jul 6. No abstract available.

PMID:
25001200
9.

Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.

Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D; ESMO; ESSO; ESTRO.

Radiother Oncol. 2014 Jun;111(3):330-9. doi: 10.1016/j.radonc.2014.04.013. Epub 2014 Jun 16.

10.

Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME, Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L.

J Clin Oncol. 2011 Jul 10;29(20):2773-80. doi: 10.1200/JCO.2010.34.4911. Epub 2011 May 23.

PMID:
21606427
11.

Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).

Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Garufi C, Bochicchio A, Rosati G, Aprile G, Giaquinta S, Torri V, Bardelli A, Gion M, Martoni A.

Ann Oncol. 2011 Nov;22(11):2424-30. doi: 10.1093/annonc/mdq782. Epub 2011 Mar 8.

PMID:
21385884
12.

Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials.

Gerard JP, Rostom Y, Gal J, Benchimol D, Ortholan C, Aschele C, Levi JM.

Crit Rev Oncol Hematol. 2012 Jan;81(1):21-8. doi: 10.1016/j.critrevonc.2011.02.001. Epub 2011 Mar 5. Review.

PMID:
21377377
13.

Chemotherapy for operable and advanced colorectal cancer.

Aschele C, Bergamo F, Lonardi S.

Cancer Treat Rev. 2009 Oct;35(6):509-16. doi: 10.1016/j.ctrv.2009.04.003. Epub 2009 May 29. Review.

PMID:
19481872
14.

Multidisciplinary treatment of rectal cancer: medical oncology.

Aschele C, Lonardi S.

Ann Oncol. 2007 Nov;18(11):1908-15. No abstract available.

PMID:
18198494
15.

Multidisciplinary treatment of rectal cancer: medical oncology.

Aschele C, Lonardi S.

Ann Oncol. 2007 Jul;18 Suppl 9:ix114-21. Review. No abstract available. Corrected and republished in: Ann Oncol. 2007 Nov;18(11):1908-15.

PMID:
17631563
16.

Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer.

Aschele C, Lonardi S.

J Clin Oncol. 2007 Feb 10;25(5):602-3; author reply 603. No abstract available.

PMID:
17290071
17.

[Metastatic colorectal cancer: adjournments from ESMO 2006].

Bonetti A, Cascinu S, Falcone A, Maiello E, Zaniboni A, Aschele C.

Tumori. 2006 Nov-Dec;92(6):1-12. Italian. No abstract available.

PMID:
17262903
18.

5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.

Pucciarelli S, Urso E, DeSalvo GL, Aschele C, Friso ML, Rugge M, Toppan P, Bruttocao A, Fabris G, Ferraro B, Lonardi S, Frego M, Finco C, Lise M, Nitti D.

Arch Med Res. 2006 Oct;37(7):860-5.

PMID:
16971226
19.

Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.

Urso E, Serpentini S, Pucciarelli S, De Salvo GL, Friso ML, Fabris G, Lonardi S, Ferraro B, Bruttocao A, Aschele C, Nitti D.

Eur J Surg Oncol. 2006 Dec;32(10):1201-8. Epub 2006 Jul 26.

PMID:
16872799
20.

A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.

Aschele C, Friso ML, Pucciarelli S, Lonardi S, Sartor L, Fabris G, Urso ED, Del Bianco P, Sotti G, Lise M, Monfardini S.

Ann Oncol. 2005 Jul;16(7):1140-6. Epub 2005 May 13.

PMID:
15894548
21.
22.

Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma.

Jodrell DI, Evans TR, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C, Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B, De Braud F.

Eur J Cancer. 2004 Aug;40(12):1872-7.

PMID:
15288289
23.

Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.

Belvedere O, Puglisi F, Di Loreto C, Cataldi P, Guglielmi A, Aschele C, Sobrero A.

Ann Oncol. 2004 Jan;15(1):55-8.

PMID:
14679120
24.

Radiochemotherapy in rectal cancer: the role of oxaliplatin.

Gerard JP, Glynne-Jones R, Blackstock W, Aschele C, van de Velde C.

Colorectal Dis. 2003 Nov;5 Suppl 3:29-35. Review.

PMID:
23573558
25.

Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil.

Aschele C, Debernardis D, Bandelloni R, Cascinu S, Catalano V, Giordani P, Barni S, Turci D, Drudi G, Lonardi S, Gallo L, Maley F, Monfardini S.

Ann Oncol. 2002 Dec;13(12):1882-92.

PMID:
12453856
26.
27.

Indications and feasibility of adjuvant chemotherapy in elderly patients with colorectal cancer.

Aschele C, Sartor L, Lonardi S.

Tumori. 2002 Jan-Feb;88(1 Suppl 1):S113-4. No abstract available.

PMID:
11989901
29.

5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.

Sobrero A, Guglielmi A, Cirillo M, Recaldin E, Frassineti GL, Aschele C, Ravaioli A, Testore P, Caroti C, Gallo L, Pessi MA, Cortesi E, Turci D, Grossi F, Labianca R.

Br J Cancer. 2001 Apr 20;84(8):1023-8.

30.

[Molecular factors predictive of response to chemotherapy in advanced stages of colorectal cancer].

Aschele C, Lonardi S, Monfardini S.

Tumori. 2001 Jan-Feb;87(1 Suppl 1):S77-9. Italian. No abstract available.

PMID:
11300036
32.

Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.

Sobrero A, Zaniboni A, Frassineti GL, Aschele C, Guglielmi A, Giuliani R, Ravaioli A, Lanfranco C, Caroti C, Arnoldi E, Barni S, Gallo L, Pessi MA, Turci D, Cortesi E, Grossi F, Frontini L, Piazza E, Bruzzi P, Labianca R.

Ann Oncol. 2000 Nov;11(11):1413-20.

PMID:
11142481
33.

Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.

Sobrero A, Guglielmi A, Grossi F, Puglisi F, Aschele C.

Semin Oncol. 2000 Oct;27(5 Suppl 10):72-7. Review. No abstract available.

PMID:
11049035
34.

Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combination.

Cascinu S, Catalano V, Aschele C, Barni S, Debernardis D, Gallo L, Bandelloni R, Staccioli MP, Baldelli AM, Brenna A, Valenti A, Muretto P, Catalano G.

Ann Oncol. 2000 Aug;11(8):1053-6.

PMID:
11038045
35.

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.

Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A.

J Clin Oncol. 1999 Jun;17(6):1760-70.

PMID:
10561213
36.

Thymidylate synthase protein expression in advanced colon cancer: correlation with the site of metastasis and the clinical response to leucovorin-modulated bolus 5-fluorouracil.

Cascinu S, Aschele C, Barni S, Debernardis D, Baldo C, Tunesi G, Catalano V, Staccioli MP, Brenna A, Muretto P, Catalano G.

Clin Cancer Res. 1999 Aug;5(8):1996-9.

37.

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.

Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR.

Clin Cancer Res. 1998 May;4(5):1323-30.

38.

Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.

Aschele C, Guglielmi A, Frassineti GL, Milandri C, Amadori D, Labianca R, Vinci M, Tixi L, Caroti C, Ciferri E, Verdi E, Rosso R, Sobrero A.

Br J Cancer. 1998;77(2):341-6.

39.

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.

Sobrero AF, Aschele C, Bertino JR.

J Clin Oncol. 1997 Jan;15(1):368-81. Review.

PMID:
8996164
40.
41.

In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.

Guglielmi A, Aschele C, Mori A, Baldo C, Russo P, Debernardis D, Valenti M, Bruno S, Taverna M, Rosso R, et al.

Clin Cancer Res. 1995 Nov;1(11):1337-44.

42.

Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.

Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Tixi LM, Bolli EA, Rosso R, Mammoliti S, Rollandi GA, Bertoglio S, et al.

Clin Cancer Res. 1995 Sep;1(9):955-60.

43.

Ondansetron for the control of dacarbazine-induced emesis.

Campora E, Chiara S, Aschele C.

Eur J Cancer. 1995 Sep;31A(10):1720-1. No abstract available.

PMID:
7488437
44.

Adjuvant Treatment of Colorectal Cancer in the Elderly.

Aschele C, Guglielmi A, Tixi LM, Bolli E, Mori AM, Lionetto R, Rosso R, Sobrero A.

Cancer Control. 1995 Mar;2(2 Suppl 1):36-38.

PMID:
10887408
45.

5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas).

Bolli E, Saccomanno S, Mondini G, Aschele C, Guglielmi A, Ligas B, Connio M, Mori A, Rosso R, Sobrero A, et al.

Cancer Chemother Pharmacol. 1995;35(4):339-42.

PMID:
7828278
46.

Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.

Sobrero AF, Aschele C, Guglielmi AP, Mori AM, Melioli GG, Rosso R, Bertino JR.

J Natl Cancer Inst. 1993 Dec 1;85(23):1937-44.

PMID:
8230285
47.

Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance.

Wang FS, Aschele C, Sobrero A, Chang YM, Bertino JR.

Cancer Res. 1993 Aug 15;53(16):3677-80.

48.

Dacarbazine and fotemustine in advanced colorectal cancer.

Tixi L, Bolli E, Guglielmi A, Mori A, Aschele C, Nobile MT, Rosso R, Sobrero A.

Eur J Cancer. 1993;29A(3):476. No abstract available.

PMID:
8398352
49.

Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil.

Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A.

Cancer Chemother Pharmacol. 1993;33(2):179-80.

PMID:
8261580
50.

Standard indication of immunotherapy for the treatment of cancer.

Bolli E, Tixi L, Mori A, Guglielmi A, Aschele C, Rovini E, Sobrero A.

Pharmacol Res. 1992 Sep;26 Suppl 2:100-1. No abstract available.

PMID:
1384019

Supplemental Content

Loading ...
Support Center